<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Singh CSB</submitter><funding>Centre for Blood Research, University of British Columbia</funding><funding>Canadian Institutes of Health Research</funding><funding>Victoria University</funding><funding>W. Garfield Weston Foundation</funding><pagination>103503</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8449085</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>71</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Cognitive decline leading to dementia, accompanied by the accumulation of amyloid-beta (Aβ) in neuritic plaques together with the appearance of neurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein (tau), are previously noted hallmarks of Alzheimer's disease (AD). We previously discovered hypervascularity in brain specimens from AD patients and consistent with this observation, we demonstrated that overexpression of Aβ drives cerebrovascular neoangiogenesis leading to hypervascularity and coincident tight-junction disruption and blood-brain barrier (BBB) leakiness in animal models of AD. We subsequently demonstrated that amyloid plaque burden and cerebrovascular pathogenesis subside when pro-angiogenic Aβ levels are reduced. Based on these data, we pr</pubmed_abstract><journal>EBioMedicine</journal><pubmed_title>Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics.</pubmed_title><pmcid>PMC8449085</pmcid><funding_grant_id>RR161038</funding_grant_id><funding_grant_id>MOP-133635</funding_grant_id><pubmed_authors>Jefferies WA</pubmed_authors><pubmed_authors>Munro L</pubmed_authors><pubmed_authors>Pfeifer CG</pubmed_authors><pubmed_authors>Choi KB</pubmed_authors><pubmed_authors>Singh CSB</pubmed_authors><pubmed_authors>Wang HY</pubmed_authors></additional><is_claimable>false</is_claimable><name>Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics.</name><description>&lt;h4>Background&lt;/h4>Cognitive decline leading to dementia, accompanied by the accumulation of amyloid-beta (Aβ) in neuritic plaques together with the appearance of neurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein (tau), are previously noted hallmarks of Alzheimer's disease (AD). We previously discovered hypervascularity in brain specimens from AD patients and consistent with this observation, we demonstrated that overexpression of Aβ drives cerebrovascular neoangiogenesis leading to hypervascularity and coincident tight-junction disruption and blood-brain barrier (BBB) leakiness in animal models of AD. We subsequently demonstrated that amyloid plaque burden and cerebrovascular pathogenesis subside when pro-angiogenic Aβ levels are reduced. Based on these data, we pr</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Sep</publication><modification>2026-05-27T21:52:20.487Z</modification><creation>2022-02-11T11:17:36.63Z</creation></dates><accession>S-EPMC8449085</accession><cross_references><pubmed>34534764</pubmed><doi>10.1016/j.ebiom.2021.103503</doi></cross_references></HashMap>